SCHEMBL8978726

SCHEMBL8978726

CNN(C)c1ccc(Br)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 5/20 0.53
ALDH1A1 P00352 3/20 0.37
NPC1 O15118 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
RAB9A P51151 2/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 2/20 0.36
MAPK1 P28482 1/20 0.36
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
ADRA2A P08913 2/20 0.32
ADRA2B P18089 2/20 0.32
ADRA2C P18825 2/20 0.32
PLAU P00749 1/20 0.32
SSTR2 P30874 1/20 0.32
SSTR4 P31391 1/20 0.32
EGFR P00533 2/20 0.32
EDNRA P25101 1/20 0.32
FDPS P14324 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL304232 0.79 GBA1 (0.61) GBA1ALDH1A1NPC1SMN1; SMN2RAB9A
SCHEMBL8981309 0.76 TDO2 (0.35) ALDH1A1KMT2AKDM4EJAK2JAK1
SCHEMBL4112757 0.75 GBA1 (0.57) GBA1ALDH1A1NPC1SMN1; SMN2RAB9A
SCHEMBL5237488 0.73 GBA1 (0.60) GBA1ALDH1A1NPC1SMN1; SMN2RAB9A
SCHEMBL1433090 0.72 GBA1 (0.69) GBA1ALDH1A1NPC1SMN1; SMN2RAB9A
SCHEMBL31217405 0.72 GBA1 (0.53) GBA1ALDH1A1NPC1SMN1; SMN2RAB9A
SCHEMBL11999256 0.72 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2KDM4EFDPS
SCHEMBL9031964 0.72 AOC3 (0.34) GBA1MAPTKMT2A
SCHEMBL8979076 0.72 L3MBTL1 (0.48) ALDH1A1NPC1SMN1; SMN2RAB9AMAPT
SCHEMBL16230817 0.71 GBA1 (0.57) GBA1ALDH1A1NPC1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD GBA1 3323/4885ALDH1A1 467/4885NPC1 3153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.